Probiotic Composition for Vaginosis Treatment via pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial vaginosis often lead to recurrence due to the killing of beneficial normal flora along with causative bacteria, and existing remedies provide only temporary relief without ensuring complete recovery.
Innovation Solution
A composition containing Steroidobacter denitrificans YH1 and Lactobacillus crispatus YH2 strains, along with a buffer like sodium phosphate tribasic and citric acid, is used to create an environment that inhibits the growth of pathogens causing vaginosis, restoring the vaginal ecosystem and reducing recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics (metronidazole or clindamycin) are used to kill causative bacteria of bacterial vaginosis, then the causative bacteria are eliminated, but beneficial normal flora are also killed causing frequent recurrence
Solution Approach 1:
The patent extracts and isolates specific beneficial lactic acid bacteria strains (Lactobacillus crispatus YH2 and Steroidobacter denitrificans YH1) from the vaginal flora. These isolated strains are then applied therapeutically to replace the harmful antibiotics, providing targeted treatment that eliminates pathogens while preserving and restoring beneficial flora through probiotic supplementation.
Solution Approach 2:
The patent changes the therapeutic approach from antimicrobial (killing bacteria) to probiotic (introducing beneficial bacteria). By altering the pH parameter through lactic acid production by the introduced strains and maintaining vaginal acidity at optimal levels, the treatment creates an environment unfavorable to pathogens while promoting growth of beneficial flora, thereby preventing recurrence.
2Object-affected harmful factors
If vaginal cleansers containing iodine compounds are used to kill bacteria, then bacterial growth is inhibited temporarily, but all bacteria in the vagina are killed leading to recurrence
Solution Approach 1:
The patent employs self-service mechanism where the introduced lactic acid bacteria strains (Lactobacillus crispatus YH2 and Steroidobacter denitrificans YH1) continuously produce lactic acid and maintain vaginal pH levels autonomously. This creates a self-sustaining therapeutic effect that prevents pathogen growth without requiring repeated application of harsh antimicrobial agents, thereby extending the duration of action and preventing recurrence.
3Reliability
If lactic acid bacteria are injected directly into the vagina to inhibit causative bacteria, then some therapeutic effect is achieved, but the effect is slight and not commercially viable
Solution Approach 1:
The patent uses a composite probiotic formulation containing two specifically selected bacterial strains: Lactobacillus crispatus YH2 and Steroidobacter denitrificans YH1. This composite approach synergistically combines the benefits of both strains - L. crispatus for lactic acid production and pH maintenance, and S. denitrificans for additional antimicrobial activity and ecological balance - thereby significantly enhancing the therapeutic effect compared to single-strain applications and making the treatment commercially viable.
Data Source
AI summary
Disclosed is a method of treating vaginosis with a composition having Steroidobacter denitrificans YH1 (KCTC18345P) and Lactobacillus crispatus YH2 (KCTC18346P) strains, wherein the composition further includes at least one buffer selected from the group consisting of sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, citric acid, sodium citrate, phosphoric acid, hydrochloric acid, sodium hydroxide, sodium pyrophosphate, and pyrophosphate.